Moderna Vaccine Application Advances After Prasad Overrules FDA Scientists
FDA CBER deputy director Dr. Vinay Prasad overruled career FDA scientists who flagged data deficiencies in Moderna’s mRNA vaccine application, forwarding it to an external advisory committee. The decision highlights regulatory tensions that could introduce volatility in Moderna’s share price.
1. Overrule Details
Dr. Vinay Prasad, deputy director of the FDA’s Center for Biologics Evaluation and Research, dismissed career scientists’ recommendations to request more data on Moderna’s mRNA vaccine application and advanced the file directly to an external advisory committee.
2. Regulatory Implications
The move exposes potential conflicts between political appointees and career reviewers at the FDA, prompting scrutiny over whether scientific rigor is being maintained in Moderna’s vaccine assessments.
3. Investor Implications
Analysts warn that perceived regulatory interference may heighten uncertainty around Moderna’s pipeline approvals, likely increasing share price volatility as investors assess the company’s near-term outlook.